Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

Fig. 1

Patients younger than 2 years of age: patient disposition. aTwo patients completed the OEP upon reaching age 2, 1 at week 20 and 1 at week 56; 3 patients completed the OEP (last dose), 2 at week 50 and 1 at week 48. AE: adverse event; MEP: main evaluation period; OEP: optional extension period; Q2W: every 2 weeks; TCZ: tocilizumab

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096